Monday, October 1, 2012
One Year On Herceptin For Breast Cancer Ideal - Medical News Today
Moneycontrol.comOne Year On Herceptin For Breast Cancer IdealMedical News TodayPatients in early-stage HER2-positive breast cancer should remain on Herceptin (trastuzumab) treatment for one year, and not two years or six months, according to a final analysis of the Phase III HERA trial, pharmaceutical company Roche and the Breast ...Herceptin data fends off $ 1.5B threat to Roche salesFiercePharmaCurrent Length of Herceptin Cancer Treatment Is Supported by StudiesNew York TimesCancer trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment